UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 224, 2017

______________

AOXING PHARMACEUTICAL COMPANY, INC.

(Exact name of registrant as specified in its charter)

______________

Florida	0-24185	65-0636168
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1098 Foster City Blvd., Suite 106-810, Foster City, CA 94404

(Address of Principal Executive Office) (Zip Code)

(646) 367 1747

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~Indicate 5by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.~~07 Submission~~405 of ~~Matters~~this tochapter) aor ~~Vote~~Rule 12b-2 of ~~Security~~the ~~Holders~~Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

OnEmerging ~~June~~growth ~~22, 2017, Aoxing Pharmaceutical Company, Inc. (the "Company") held its annual shareholder meeting. The shareholders approved the following proposals:~~company ☐

~~Proposal~~If 1an -emerging ~~Election~~growth ~~of Directors. The shareholders elected Zhenjiang Yue~~company, ~~Jun~~indicate ~~Min,~~by ~~Guozhu~~check ~~Xu,~~mark ~~Yang~~if Lithe ~~and~~registrant ~~Yuelin~~has ~~Zhang~~elected asnot ~~directors~~ to ~~hold~~use ~~office~~the ~~until~~extended ~~the~~transition ~~next~~period ~~annual~~for ~~meeting~~complying ofwith ~~shareholders~~any ~~and~~new ~~until~~or ~~their~~revised ~~successors~~financial ~~are~~accounting ~~duly~~standards ~~elected.~~provided Apursuant ~~summary~~to Section 13(a) of ~~votes~~the ~~cast~~Exchange ~~follows~~Act. ~~below:~~☐

Nominee	Votes for		Votes Withheld		Broker Non-Votes
Zhenjiang Yue		45,917,521		34,044		0
Jun Min		45,917,242		34,323		0
Guozhu Xu		45,905,123		46,442		0
Yang Li		45,918,021		33,544		0
Yuelin Zhang		45,918,232		33,333		0

Item 5.02

Departure of Directors or Certain Officers; Appointment of Certain Officers

~~Proposal~~On 2August -4, To2017 ~~ratify~~Zheng ~~the~~James ~~appointment~~Chen ofresigned ~~BDO~~from ~~China~~his ~~Shu~~position ~~Lun~~as ~~Pan~~the ~~Certified~~Registrant's ~~Accountants,~~Chief ~~LLP~~Financial asOfficer. On ~~independent~~August ~~registered~~4, ~~public~~2017, ~~accounting~~the ~~firm~~Board of Directors appointed Guoan Zhang to serve as the ~~Company~~Registrant's Chief ~~for~~Financial Officer,. Mr. Zhang has been the ~~fiscal~~Registrant's ~~year~~Senior ~~ending~~Vice President of Finance since June ~~30,~~2010 ~~2017~~and Chief Accounting Officer since March 2010. ~~This~~ ~~proposal~~Mr. ~~was~~Zhang ~~approved~~also ~~with~~served ~~46,278,135~~as ~~shares~~the ~~voting~~Registrant's ~~for~~Acting ~~and~~Chief ~~7,349 shares~~Financial ~~voting~~Officer ~~against~~from itJuly ~~(with~~2012 13to December 2014 and November 30,~~416~~ ~~abstaining~~2015 ~~votes)~~to January 27, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Aoxing Pharmaceutical Company, Inc.
Date: June 22, 2017	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer
Date: August 4, 2017	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer

Filing Compare · AOXING PHARMACEUTICAL COMPANY, INC.